Quality & complianceOfficial

Denmark reports November supply problems for MSD's CAPVAXIVE pneumococcal vaccine, citing higher demand

🇩🇰 DKMA · Thu 05 Nov 2026

The Danish Medicines Agency says pre-filled syringes of CAPVAXIVE from MSD Danmark are affected, with disruption expected from early to late November 2026 due to increased sales.

The Danish Medicines Agency (DKMA) has published a supply notice for CAPVAXIVE solution for injection in pre-filled syringes, marketed in Denmark by MSD Danmark ApS. The notice, dated 5 November 2026, states that there are current problems with supply of the product.

DKMA gives the expected period of disruption as the start of November to the end of November 2026. The stated cause is increased sales and demand. The notice does not say how many packs or presentations are affected, nor how severe the shortfall is.

The vaccine's active substance is listed as pneumococcal polysaccharide of 21 serotypes, conjugated to CRM197, under ATC code J07AL02. The notice does not mention alternative products, substitution advice or recommendations for vaccination programmes.

DKMA directs anyone with questions about the current status to the company. The notice sits within the agency's regular announcements on medicine supply, which flag supply difficulties reported to it.

What it means for your team

  • Teams with Danish exposure should check current CAPVAXIVE stock and ordering status directly with MSD Danmark ApS, as DKMA refers status queries to the company.
  • The notice gives no detail on alternatives or clinical guidance, so any contingency planning will need to draw on other sources.
  • The disruption is attributed to demand rather than a quality or safety issue, and the stated window is November 2026; companies should watch for any update to that timeline.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →